Randomized prospective investigation of recurrence and progression between intra-artery chemotherapy and intravesical treatment for T1G3 bladder cancer

Comparison of recurrence and progression between intra-artery chemotherapy and intravesical treatment for T1G3 bladder cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16007877

Enrollment

Unknown

Registered

2016-02-02

Start date

2016-02-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

1:chemotherapy

2:intravesical instillation

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. T1G3 bladder cancer without adenocarcinoma or squamous cell carcinoma; 2. aged from 18-80 years old, expected life>2 years, ECOG score from 0-2; 3. good function of main organs: liver, kidney, bone marrow, heart and etc.; 4. understanding this study and signed informed constent.

Exclusion criteria

Exclusion criteria: 1. prior treatment with intravesical BCG or chemotherapy of Gemcitabine and Cisplatin; 2. muscle-invasive or metastatic bladder cancer; 3. be allergic to BCG; 4. be pregnant or in breast-feeding period.

Design outcomes

Primary

Measure	Time frame
2-year recurrence rate;	—

Secondary

Measure	Time frame
4-year progress rate;5-year cancer-specific survival rate;4-year bladder-sparing rate;	—

Countries

China

Contacts

Public ContactZhou Fang-jian

zhoufj@sysucc.org.cn+86 13922735659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026